3.28亿美元！CSL与Memo达成抗体技术战略合作

市场资讯02-09

（来源：药研网）2026年2月9日，Memo Therapeutics AG宣布，已与全球罕见病及重症药物研发领导者CSL就MTx重组多克隆IgG技术达成战略合作及独家许可选择权协议。根据合作与选择协议，MTx将利用其专有的DROPZYLLA®技术平台开发重组多克隆IgG产品，该平台用于克隆人类抗体库和多克隆抗体表达，CSL则获得MTx的独家许可权。协议总额最高可达2.65亿瑞士法郎（3.28...

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2610636967?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-09 17:45","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2610636967","market":"sh","top_or_hot":-1,"title":"3.28亿美元！CSL与Memo达成抗体技术战略合作","media":"市场资讯","content":"<div>\n<p>（来源：药研网）2026年2月9日，Memo Therapeutics AG宣布，已与全球罕见病及重症药物研发领导者CSL就MTx重组多克隆IgG技术达成战略合作及独家许可选择权协议。根据合作与选择协议，MTx将利用其专有的DROPZYLLA®技术平台开发重组多克隆IgG产品，该平台用于克隆人类抗体库和多克隆抗体表达，CSL则获得MTx的独家许可权。协议总额最高可达2.65亿瑞士法郎（3.28...</p>\n\n<a href=\"https://finance.sina.com.cn/roll/2026-02-09/doc-inhmfive5366908.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3.28亿美元！CSL与Memo达成抗体技术战略合作</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3.28亿美元！CSL与Memo达成抗体技术战略合作\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-09 17:45 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/roll/2026-02-09/doc-inhmfive5366908.shtml><strong>市场资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>（来源：药研网）2026年2月9日，Memo Therapeutics AG宣布，已与全球罕见病及重症药物研发领导者CSL就MTx重组多克隆IgG技术达成战略合作及独家许可选择权协议。根据合作与选择协议，MTx将利用其专有的DROPZYLLA®技术平台开发重组多克隆IgG产品，该平台用于克隆人类抗体库和多克隆抗体表达，CSL则获得MTx的独家许可权。协议总额最高可达2.65亿瑞士法郎（3.28...</p>\n\n<a href=\"https://finance.sina.com.cn/roll/2026-02-09/doc-inhmfive5366908.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1169590202.USD","symbol_name":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","start_time":0,"source_url":"https://finance.sina.com.cn/roll/2026-02-09/doc-inhmfive5366908.shtml","article_id":"2610636967","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610636967","pubTimestamp":1770630300,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"2026年2月9日，Memo Therapeutics AG宣布，已与全球罕见病及重症药物研发领导者CSL就MTx重组多克隆IgG技术达成战略合作及独家许可选择权协议。根据合作与选择协议，MTx将利用其专有的DROPZYLLA技术平台开发重组多克隆IgG产品，该平台用于克隆人类抗体库和多克隆抗体表达，CSL则获得MTx的独家许可权。协议总额最高可达2.65亿瑞士法郎。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK4086":"建筑产品","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","CSL":"卡莱尔伙伴"},"translate_title":"$328 million! CSL and Memo reach strategic cooperation on antibody technology","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL":1.5},"content_text":"（来源：药研网）2026年2月9日，Memo Therapeutics AG宣布，已与全球罕见病及重症药物研发领导者CSL就MTx重组多克隆IgG技术达成战略合作及独家许可选择权协议。根据合作与选择协议，MTx将利用其专有的DROPZYLLA®技术平台开发重组多克隆IgG产品，该平台用于克隆人类抗体库和多克隆抗体表达，CSL则获得MTx的独家许可权。协议总额最高可达2.65亿瑞士法郎（3.28亿美元）。DROPZYLLA®平台是一项基于重组多克隆抗体（recombinant polyclonal IgG）的创新技术平台，该技术能够大规模捕获并复制天然人源抗体库，从而实现多样化抗体群体的稳定可控表达，这些抗体可针对特定感染性或免疫介导性疾病进行定制。MTx首席执行官Erik van den Berg表示：“IgG免疫疗法被用于治疗包括先天性或获得性免疫缺陷以及自身免疫疾病在内的多种疾病。”“与CSL的合作进一步验证了我们专有的DROPZYLLA®技术平台，以及我们共同推进创新IgG解决方案的雄心。”CSL全球研究高级副总裁Michael Wilson博士评论道：“此次研究合作结合了CSL在免疫球蛋白领域的全球领先地位和重组蛋白专业知识，以及Memo Therapeutics的重组多克隆技术，探索为罕见和严重疾病患者开辟新的治疗方案。”\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610636967","isCrawlerRequest":true}